News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alethia BioTherapeutics, Inc. and Emerillon Therapeutics Inc. Announce Collaborative Agreement for Target Discovery in Bone-Related Diseases


5/1/2007 11:01:55 AM

MONTREAL, QUEBEC -- (MARKET WIRE) -- May 01, 2007 -- Alethia Biotherapeutics Inc. and Emerillon Therapeutics Inc, both privately held biotechnology companies, announced today that they have signed a collaborative research agreement to conduct a discovery and functional validation program to identify new drug candidates for the treatment of bone-related diseases such as osteoporosis. Under the terms of the collaboration, Emerillon will provide Alethia with a list of genetic loci that are associated with an osteoporotic phenotype in mice. In return, Alethia will generate bone-specific cDNA libraries to help identify these genes. Furthermore, Alethia will conduct cell-based validation studies to determine the functional relevance of the genes provided by Emerillon.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES